Downregulation of MicroRNA-135 Promotes Sensitivity of Non-Small Cell Lung Cancer to Gefitinib by Targeting TRIM16

Wang, Ning; Zhang, Tingting

doi:10.3727/096504017x15144755633680

Cited by 45 publications

(27 citation statements)

References 35 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other miRNAs include: miR-140 (79,101,102), miR-142-5p (103,104), miR-197 (105,106), miR-34a (95,107,108), and miR-424/424-5p (109,110). miRNAs that positively regulate PD-L1 expression include miR-135 (96) and miR-3127-5p (111) in NSCLC and miR-18a in cervical cancer (79). In colorectal cancer PTEN is directly targeted by miRNAs miR-130b, miR-20b, and miR-21 to indirectly induce PD-L1 expression via PI3K-AKT-mTOR pathway activation (71).…”

Section: Epigenetic Mechanisms Modulate Pd-l1 Expressionmentioning

confidence: 99%

The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment

et al. 2020

View full text Add to dashboard Cite

Programmed death-ligand 1 (PD-L1) is an immune checkpoint inhibitor that binds to its receptor PD-1 expressed by T cells and other immune cells to regulate immune responses; ultimately preventing exacerbated activation and autoimmunity. Many tumors exploit this mechanism by overexpressing PD-L1 which often correlates with poor prognosis. Some tumors have also recently been shown to express PD-1. On tumors, PD-L1 binding to PD-1 on immune cells promotes immune evasion and tumor progression, primarily by inhibition of cytotoxic T lymphocyte effector function. PD-1/PD-L1-targeted therapy has revolutionized the cancer therapy landscape and has become the first-line treatment for some cancers, due to their ability to promote durable anti-tumor immune responses in select patients with advanced cancers. Despite this clinical success, some patients have shown to be unresponsive, hyperprogressive or develop resistance to PD-1/PD-L1-targeted therapy. The exact mechanisms for this are still unclear. This review will discuss the current status of PD-1/PD-L1-targeted therapy, oncogenic expression of PD-L1, the new and emerging tumor-intrinisic roles of PD-L1 and its receptor PD-1 and how they may contribute to tumor progression and immunotherapy responses as shown in different oncology models.

show abstract

Section: Epigenetic Mechanisms Modulate Pd-l1 Expressionmentioning

confidence: 99%

The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment

et al. 2020

View full text Add to dashboard Cite

show abstract

“…For example, miR-18a enhanced PD-L1 expression in cervical cancer by targeting the tumor suppressor PTEN and the Wnt/β-catenin pathway inhibitor SOX6 to activate the PI3K/AKT, MEK/ERK and Wnt/β-catenin pathways, respectively [ 111 ]. miR-20b, -21 and -130b upregulated PD-L1 expression in colorectal cancer also by targeting PTEN [ 112 ], while miR-135 augmented PD-L1 expression in lung cancer by suppressing the ubiquitination of proteins in the JAK/STAT signaling pathway [ 113 ].…”

Section: Expression Of Pd-l1 By Tumor Cellsmentioning

confidence: 99%

Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy

Shklovskaya

Rizos

2020

IJMS

View full text Add to dashboard Cite

Immunotherapies blocking immune inhibitory receptors programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) on T-cells have dramatically improved patient outcomes in a range of advanced cancers. However, the lack of response, and the development of resistance remain major obstacles to long-term improvements in patient outcomes. There is significant interest in the clinical use of biomarkers to improve patient selection, and the expression of PD-1 ligand 1 (PD-L1) is often reported as a potential biomarker of response. However, accumulating evidence suggests that the predictive value of PD-L1 expression in tumor biopsies is relatively low due, in part, to its complex biology. In this review, we discuss the biological consequences of PD-L1 expression by various cell types within the tumor microenvironment, and the complex mechanisms that regulate PD-L1 expression at the genomic, transcriptomic and proteomic levels.

show abstract

“…The conventional treatment for lung cancer is whole-body chemotherapy with cisplatin, but the efficacy of such regimens is limited [ 5 ]. Although several biomarkers have been reported with lung cancer prognosis, including ELF3 [ 6 ], miRNA-135 [ 7 ], miRNA-34 [ 8 ], the survival status of lung cancer patients are still not satisfactory. Thus, further studies focusing on the mechanisms of initiation and progression, and the identification of prognostic molecular markers are of crucial significance.…”

Section: Introductionmentioning

confidence: 99%

Distinct Prognostic Values of Alcohol Dehydrogenase Family Members for Non-Small Cell Lung Cancer

et al. 2018

View full text Add to dashboard Cite

BackgroundNon-small cell lung cancer (NSCLC) is a leading cause of cancer-related death worldwide. The relationships of alcohol dehydrogenase (ADH) enzymes, encoded by the genes ADH1 (1A), ADH1B (ADH2), ADH1C (ADH3), ADH4, ADH5, ADH6, and ADH7, with NSCLC have not been studied. The aim of this study was to explore the associations between NSCLC prognosis and the expression patterns of ADH family members.Material/MethodsThe online resource Metabolic gEne RApid Visualizer was used to assess the expression patterns of ADH family members in normal and primary lung tumor tissues. The GeneMANIA plugin of Cytoscape software and STRING website were used to evaluate the relationships of the 7 ADH family members at the gene and protein levels. Gene ontology enrichment analysis and KEGG pathway analysis were performed using DAVID. The online website Kaplan-Meier Plotter was used to construct survival curves between NSCLC and ADH isoforms.ResultsThe prognosis of patients with high expression levels of the ADH1B, ADH1C, ADH4, and ADH5 genes was better than those with low expression in adenocarcinoma and all (containing adenocarcinoma and squamous cell cancer) histological types (all P<0.05). Low expression of ADH7 was associated with a better prognosis in patients with both the adenocarcinoma and squamous cell cancer histological types (P=9e-05). Moreover, expression of ADH family members was associated with smoking status, clinical stage, and chemotherapy status.ConclusionsADH1B, ADH1C, ADH4, ADH5, and ADH7 appear to be useful biomarkers for the prognosis of NSCLC patients.

show abstract

Downregulation of MicroRNA-135 Promotes Sensitivity of Non-Small Cell Lung Cancer to Gefitinib by Targeting TRIM16

Cited by 45 publications

References 35 publications

The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment

The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment

Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy

Distinct Prognostic Values of Alcohol Dehydrogenase Family Members for Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About